Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study

BACKGROUND: Glycopyrronium is a once-daily (od) long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The GLOW7 study evaluated the efficacy and safety of od glycopyrronium 50 μg in predominantly Chinese patients with moderate-to-severe COPD...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Chron Obstruct Pulmon Dis
Päätekijät: Wang, Chen, Sun, Tieying, Huang, Yijiang, Humphries, Michael, Bai, Lingyan, Li, Lilly, Wang, Qian, Kho, Pearl, Firth, Roz, D’Andrea, Peter
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2015
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4293291/
https://ncbi.nlm.nih.gov/pubmed/25609940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S72650
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia